Kawahara Takashi, Ninomiya Sahoko, Miyoshi Yasuhide, Yao Masahiro, Uemura Hiroji
Department of Urology and Renal Transplantation Yokohama City University Medical Center Yokohama Japan.
Department of Urology Yokohama City University Graduate School of Medicine Yokohama Japan.
IJU Case Rep. 2019 Mar 18;2(3):143-145. doi: 10.1002/iju5.12062. eCollection 2019 May.
In June 2018, enzalutamide began to be sold in a tablet form in Japan and Germany. We herein report the case of an improvement in prostate cancer progression due to changing enzalutamide dosage form from a capsule to a tablet.
A 76-year-old man was initially referred to our hospital for the further examination of his elevated prostate-specific antigen level (3664.0 ng/mL). He had developed castration-resistant prostate cancer 10 months after initial treatment. Treatment with enzalutamide (capsule form) was subsequently initiated. In June 2018, drug form of enzalutamide was changed from a capsule to a tablet. After switching to an enzalutamide tablet, his prostate-specific antigen level decreased significantly from 493.0 to 26.5 ng/mL.
While the reason for this prostate-specific antigen response is unclear, changing the enzalutamide form from a capsule to a tablet may have improved the adherence of drug intake and thereby resulted in castration-resistant prostate cancer control.
2018年6月，恩杂鲁胺开始在日本和德国以片剂形式销售。我们在此报告一例因将恩杂鲁胺剂型从胶囊改为片剂而使前列腺癌进展得到改善的病例。
一名76岁男性最初因前列腺特异性抗原水平升高（3664.0 ng/mL）被转诊至我院进一步检查。他在初始治疗10个月后发展为去势抵抗性前列腺癌。随后开始使用恩杂鲁胺（胶囊剂型）治疗。2018年6月，恩杂鲁胺的剂型从胶囊改为片剂。改用恩杂鲁胺片剂后，他的前列腺特异性抗原水平从493.0 ng/mL显著降至26.5 ng/mL。
虽然这种前列腺特异性抗原反应的原因尚不清楚，但将恩杂鲁胺剂型从胶囊改为片剂可能改善了药物摄入的依从性，从而实现了去势抵抗性前列腺癌的控制。
